Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. (Q36072569)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Vasilios Panagopoulos

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Vasilios Liapis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Agatha Labrinidis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Irene Zinonos

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Shelley Hay

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Mark DeNichilo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

David M Findlay

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Andreas Evdokiou

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

English

0 references

publication date

15 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

357

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

160-169

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

Review of the molecular pathogenesis of osteosarcoma

23 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Recent advances in osteosarcoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

New molecular insights into osteosarcoma targeted therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

IAP-targeted therapies for cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Metastasis to bone: causes, consequences and therapeutic opportunities

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

2 October 2017

Osteolysis and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Molecular mechanisms of tumor-bone interactions in osteolytic metastases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Molecular basis of the spectrum of skeletal complications of neoplasia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Mechanisms of the development of osteoblastic metastases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Chemotherapy for osteosarcoma and Ewing's sarcoma.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

A powerful new technique for isolating genes encoding cell surface antigens using retroviral expression cloning

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574867

Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25444931

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

P-glycoprotein Expression: Critical Determinant in the Response to Osteosarcoma Chemotherapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25444931

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25444931

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.CANLET.2014.11.020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

PubMed publication ID

25444931

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25444931%20AND%20SRC:MED&resulttype=core&format=json